Role of inflammation in diabetic macular edema and neovascular age-related macular degeneration.

Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) are multifactorial disorders that affect the macula and cause significant vision loss. Although inflammation and neoangiogenesis are hallmarks of DME and nAMD, respectively, they share some biochemical mediators. While inflammation is a trigger for the processes that lead to the development of DME, in nAMD inflammation seems to be the consequence of retinal pigment epithelium and Bruch membrane alterations. These pathophysiologic differences may be the key issue that justifies the difference in treatment strategies. Vascular endothelial growth factor inhibitors have changed the treatment of both diseases, however, many patients with DME fail to achieve the established therapeutic goals. From a clinical perspective, targeting inflammatory pathways with intravitreal corticosteroids has been proven to be effective in patients with DME. On the contrary, the clinical relevance of addressing inflammation in patients with nAMD has not been proven yet. We explore the role and implication of inflammation in the development of nAMD and DME and its therapeutical relevance.

Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: S. Vujosevic is a consultant for Abbvie, Boehringer and Ingelheim, Bayer, Novartis, Roche, Zeiss. C. Astarita and V. Gallinari are AbbVie employee and may own AbbVie stocks/options. Disclosure of Conflicts of Interest This manuscript was funded by AbbVie S.r.l. AbbVie participated in writing, reviewing, and approving the publication. No honoraria or payments were made for authorship. Conflict-of-interest disclosure: S. Vujosevic is a consultant for Abbvie, Boehringer and Ingelheim, Bayer, Novartis, Roche, Zeiss. M. Lupidi, S. Donati and E. Pilotto have no conflicts of interest to declare. C. Astarita and V. Gallinari are AbbVie employee and may own AbbVie stocks/options.